Evidence map›Paper›PMID 26577445›Full record

Trial reportInternational journal of clinical oncology2016

Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).

Seiki Hasegawa, Morihito Okada, Fumihiro Tanaka, Takeharu Yamanaka, Toshinori Soejima, Norihiko Kamikonya, Tohru Tsujimura, Kazuya Fukuoka, Kohei Yokoi, Takashi Nakano

Open access · hybridAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Guideline
  2. The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017
    Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Non-incisional pleurectomy/decortication for malignant pleural mesothelioma.General thoracic and cardiovascular surgery · 2021
    Article
  16. Review
  17. Update on biology and management of mesothelioma.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Seiki HasegawaDepartment of Thoracic Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan. hasegawa@hyo-med.ac.jp.
Morihito OkadaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Fumihiro TanakaDepartment of Surgery, University of Occupational and Environmental Health, Kitakyusyu, Japan.
Takeharu YamanakaDepartment of Biostatistics, Yokohama City University, Yokohama, Japan.
Toshinori SoejimaDepartment of Radiation Oncology, Hyogo Cancer Center, Akashi, Japan.
Norihiko KamikonyaDepartment of Radiation Oncology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
Tohru TsujimuraDepartment of Pathology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
Kazuya FukuokaDepartment of Medical Oncology, Sakai Hospital, Kinki University Faculty of Medicine, Osaka, Japan.
Kohei YokoiDepartment of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi NakanoDivision of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
Hyogo Medical University · JPHiroshima University · JPHyogo Prefectural Cancer Center · JPKindai University Sakai Hospital · JPNagoya University · JPUniversity of Occupational and Environmental Health Japan · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe conducted a prospective multi-institutional study to determine the feasibility of trimodality therapy (TMT) comprising induction chemotherapy followed by extrapleural pneumonectomy (EPP) and radiation therapy in Japanese patients with malignant pleural mesothelioma (MPM).

methodsMajor eligibility criteria were histologically confirmed diagnosis of MPM, including clinical subtypes T0-3, N0-2, M0 disease; no prior treatment for the disease; age 20-75 years; Eastern Cooperative Oncology Group performance status 0 or 1; predicted postoperative forced expiratory volume >1000 ml in 1 s; written informed consent. Treatment methods comprised induction chemotherapy using pemetrexed (500 mg/m(2)) plus cisplatin (60 mg/m(2)) for three cycles, followed by EPP and postoperative hemithoracic radiation therapy (54 Gy). Primary endpoints were macroscopic complete resection (MCR) rate for EPP and treatment-related mortality for TMT.

resultsForty-two eligible patients were enrolled: median age 64.5 (range 43-74) years; M:F = 39:3, clinical stage I:II:III = 14:13:15; histological type epithelioid were sarcomatoid; biphasic; others = 28:1:9:4. Of 42 patients, 30 completed EPP with MCR and 17 completed TMT. The trial met the primary endpoints, with an MCR rate of 71 % (30/42) and treatment-related mortality of 9.5 % (4/42). Overall median survival time and 2-year survival rate for 42 registered patients were 19.9 months and 42.9 %, respectively. Two-year relapse-free survival rate of 30 patients who completed EPP with MCR was 37.0 %.

conclusionThis phase II study met the predefined primary endpoints, but its risk/benefit ratio was not satisfactory.

Indexed as

PneumonectomyAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCisplatinFeasibility StudiesFemaleHumansInduction ChemotherapyJapanMaleMesotheliomaMiddle AgedNeoadjuvant TherapyAntineoplastic AgentsCisplatinPemetrexedClinical trialsMesotheliomaPleural diseaseThoracic surgery

Identifiers

PMID26577445
PMCPMC4901093
OpenAlexW2174424137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.